AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the
Exchange Act of 1934
of Report (Date of earliest event reported): February 4, 2016 (January 31, 2016)
name of registrant as specified in its charter)
or other jurisdiction
106 Cedar Knolls, New Jersey
of principal executive offices)
telephone number, including area code (973) 509-0444
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
January 31, 2016, Dr. Robert C. Ashton, Jr., the Chief Medical Officer of MYOS Corporation (the “Company”), informed
the Company of his intention to resign his employment with the Company, effective immediately. Dr. Ashton’s resignation
is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
8.01 Other Events.
February 1, 2016, Dr. Michael Donnelly joined the Company as Head of Medical and Clinical Affairs, a newly created position
within the Company. In this position, Dr. Donnelly will lead the Company's clinical research efforts and serve on the
Company’s Scientific Advisory Board. Dr. Donnelly will also be responsible for the clinical development strategy for
Fortetropin® and identifying new indications for this MYOS Technology.
to joining the Company, Dr. Donnelly served as Executive Medical Director of Medical Affairs at Daiichi Sankyo Inc., a Japanese-based
innovation and scientific-driven pharmaceuticals company where he worked since August 2010. Before that Dr. Donnelly served in
a number of medical leadership roles. These include Medical Vice President and National Medical Director at Auto Injury Solutions,
Inc., formerly a division of Concentra Inc., from March 2008 to August 2010. From August 2001 to March 2008, Dr. Donnelly served
in a number of positions of increasing responsibility at Pfizer Inc., including Regional Corporate Medical Director from June
2004 to March 2008. Dr. Donnelly served as National Medical Director at Warner Lambert from January 1997 to January 2001. Earlier
in his career, Dr. Donnelly served as Assistant Medical Director at Novartis from January 1992 to January 1997 and Associate Medical
Director at American Cyanamid from January 1991 to January 1992. Dr. Donnelly practiced medicine as an internist and geriatrician
at the Summit Medical Group from January 1989 to January 1991. Dr. Donnelly has been an attending physician affiliated with Atlantic
Health System Hospitals in New Jersey for his entire medical career and is certified by the American Board of Internal Medicine
in Internal Medicine and Geriatric Medicine. Dr. Donnelly received his BS in Biology at the University of Scranton in 1983 and
his MD degree from the Medical College of Pennsylvania in 1987. He completed his internship and residency at Overlook Hospital/Columbia
University College of Physician and Surgeons program in 1990. He is currently a graduate student in the MBA program at University
of Massachusetts Amherst, where he is expected to receive his degree in May 2016. In addition to his formal education, Dr. Donnelly
has completed a number of post-graduate certificate programs including Certified Physician Executive (CPE) and Healthcare IT (HIT)
with the American College of Physician Executives as well as medical/business leadership programs at Harvard Business School and
the Tuck School of Business.
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Joseph C. DosSantos|
Chief Financial Officer|